A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients’ trial-Reference-Cited by-同舟云学术

A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients’ trial

Published:2015-05-06 Issue:2 Volume:96 Page:188-197
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Kim Hawk¹,Lee Je-Hwan²,Joo Young-Don³,Bae Sung Hwa⁴,Lee Jung-Hee²,Kim Dae-Young²,Lee Won-Sik⁵,Ryoo Hun-Mo⁴,Jo Jae-Cheol¹,Choi Yunsuk¹,Lee Kyoo-Hyung²,

Affiliation:

1. Division of Hematology and Cellular Therapy; Ulsan University Hospital; University of Ulsan College of Medicine; Ulsan Korea

2. Department of Hematology; Asan Medical Center; University of Ulsan College of Medicine; Ulsan Korea

3. Department of Hematology/Oncology; Haeundae Paik Hospital; Inje University College of Medicine; Busan Korea

4. Department of Hematology-Oncology; Daegu Catholic University Medical Center; Catholic University of Daegu School of Medicine; Daegu Korea

5. Department of Hematology/Oncology; Busan Paik Hospital; Inje University College of Medicine; Busan Korea

Funder

Ministry of Education, Science and Technology

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12568/fullpdf

Reference22 articles.

1. Trends in the treatment of acute myeloid leukaemia in the elderly;Lang;Drugs Aging,2005

2. Korean Society of Hematology AMLMDSwp. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients;Kim;Am J Hematol,2013

3. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group;Avramis;Clin Cancer Res,1998

4. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group;Dinndorf;J Clin Oncol,1997

5. A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara-A) and cytarabine (ara-C) for refractory or recurrent pediatric acute myeloid leukemia (AML);Leahey;J Pediatr Hematol Oncol,1997

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML;Aging;2020-04-01

2. Comparison of efficacy of HCAG and FLAG re-induction chemotherapy in acute myeloid leukemia patients of low- and intermediate-risk groups;Clinical and Translational Oncology;2019-03-26

3. Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens;Cancer Biomarkers;2018-12-06

4. Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow;Leukemia Research;2018-11

5. Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study;Bone Marrow Transplantation;2018-10-19